What is tumor heterogeneity and where does it come from?

Learn in 30 seconds

The main points of this article:

• Heterogeneity on two planes: between patients (inter) and within a tumor (intra).
• Three sources: genetic/spatial diversity, microenvironmental differences, temporal clonal selection.
• A single biopsy may not capture the full map (Gerlinger 2012 example).
• Treatment pressure can shrink sensitive clones and let resistant subclones dominate.
• Molecular tests are not mandatory for everyone; they depend on tumor type and clinical need.

Why the same cancer name does not mean the same disease

In everyday speech “the same cancer” usually means the same organ. Clinically that name is often a broad label: stage, site, pathology subtype, and sometimes molecular features sit underneath. Two planes help:

• Inter-tumoral — Two tumors from the same organ origin can behave differently.
• Intra-tumoral — Different regions of the same mass, or the same mass over time, can hold different subclones.

Source: Marusyk & Polyak 2010.

Three primary drivers (panels of the schematic)

Three commonly taught sources of tumor heterogeneity:

• Genetic and molecular diversity (spatial heterogeneity): Different regions of one mass can harbor distinct mutational profiles. Landmark example (*Gerlinger et al., NEJM 2012*): different biopsy regions of a primary renal tumor held different subclonal mutation sets — one biopsy may not reflect the whole map.
• Microenvironmental variations: Local vascular density, oxygenation (hypoxia), immune infiltration, and stroma are not uniform across a mass; they shape nutrition, growth, and response to cues, increasing diversity.
• Temporal evolution and clonal selection: Under natural change or treatment pressure (chemotherapy, targeted drugs), sensitive clones shrink while resistant subclones survive and may dominate — a core reason for resistance and recurrence.

Sources: Marusyk & Polyak 2010; Gerlinger 2012; Hanahan 2011/2022.

A simple analogy

Two streets with the same name in two cities: the sign matches, the traffic does not. Two colon cancers at the same stage: one is MSI-H / dMMR, the other is not. Both are called “colon cancer”; add-on options can differ. Heterogeneity does not make surgery worthless — in suitable patients surgery can remove visible tumor with safe margins; extra risk is discussed separately.

Biopsy, molecular testing, and re-sampling

Pathology does more than say “cancer is present.” Subtype, grade, margins, and extra features shape the plan. One biopsy is often highly valuable; intra-tumor diversity can still limit it. Primary and metastasis may differ — sometimes a new sample from a distant site is needed. Molecular tests can help choose paths in some tumor types; they are not mandatory for everyone. Liquid biopsy is discussed in selected settings; it is not the same as a routine blood test.

• Pathology and staging go under the umbrella diagnosis name.
• One sample is often enough; re-sampling may arise if disease behavior changes.
• Liquid biopsy is a special approach — not automatic screening for everyone.

What science knows

Points that are firmly accepted:

• The same diagnosis label can allow different courses.
• Inter- and intra-tumor diversity are possible.
• One sample may not perfectly represent the whole mass.
• Clonal selection under treatment pressure can contribute to resistance.
• Molecular tests are not mandatory for every patient.

Not yet settled (do not overstate)

These claims are overstated or not generalizable to every patient:

• Saying every molecular difference has automatic clinical meaning is overstated.
• Saying cells freely change identity at will is overstated.
• Saying one test maps all diversity is overstated.
• Treating a neighbor’s story as your decision document is overstated.